Skip to main content

Table 1 Baseline characteristics of HCC patients involved in this research

From: Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma

Characteristics

TCGA-LIHC dataset

(N = 365)

ICGC-LINC-JP dataset

(N = 231)

Age

  ≤ 60

173 (47.4)

49 (21.2%)

  > 60

192 (52.6)

182 (78.8%)

Gender

 Male

246 (67.4%)

170 (73.6%)

 Female

119 (32.6)

61 (26.4%)

Grade

 G1-2

230 (63.0%)

NA

 G3-4

130 (35.6%)

NA

 Unknown

5 (1.4%)

NA

T stage

 T1-2

271 (74.2%)

NA

 T3-4

91 (24.9%)

NA

 Unknown

3 (0.8%)

NA

N stage

 N0

248 (67.9%)

NA

 N1

4 (1.1%)

NA

 Unknown

113 (31.0%)

NA

M stage

 M0

263 (72.1%)

NA

 M1

3 (0.8%)

NA

 Unknown

99 (27.1%)

NA

Stage

 Stage I-II

254 (69.6%)

141 (61.0%)

 Stage III-IV

87 (23.8%)

90 (39.0%)

 Unknown

24 (6.6%)

0 (0%)

Child_Pugh class

 A

216 (59.2%)

NA

 B

21 (5.8%)

NA

 C

1 (0.2%)

NA

 Unknown

127 (34.8%)

NA

Cirrhosis

 No

132 (36.2%)

NA

 Yes

77 (21.1)

NA

 Unknown

156 (42.7%)

NA

Survival status

 Alive

235 (64.4%)

189 (81.8%)

 Deceased

130 (35.6%)

42 (18.2%)

  1. HCC hepatocellular carcinoma, TCGA The Cancer Genome Atlas, LIHC liver hepatocellular carcinoma, ICGC International Cancer Genome Consortium